Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.43 |
| ▸ | FAAH | O00519 | 4/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | AADAC | P22760 | 1/20 | 0.38 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6224787 | 0.92 | EPHX2 (0.39) | EPHX2FAAHSCN8ASCN10ATACR1 | |
| SCHEMBL6500895 | 0.82 | GPR3 (0.42) | EPHX2POLBPDE4D | |
| SCHEMBL8326071 | 0.79 | SCN8A (0.44) | SCN8ASCN10APDE4BPDE4D | |
| SCHEMBL1985337 | 0.78 | TUBB1 (0.51) | — | |
| SCHEMBL30902375 | 0.78 | LMNA (0.44) | TACR1GRM7 | |
| SCHEMBL6207509 | 0.77 | TACR1 (0.41) | EPHX2FAAHSCN8ASCN10ATACR1 | |
| SCHEMBL6208005 | 0.77 | TACR1 (0.41) | EPHX2FAAHSCN8ASCN10ATACR1 | |
| SCHEMBL7650939 | 0.77 | SLC6A4 (0.42) | EPHX2FAAHSCN8ASCN10ATACR1 | |
| SCHEMBL4939627 | 0.75 | ALDH1A3 (0.41) | SCN10ATACR1GRM7 | |
| SCHEMBL18570710 | 0.75 | SCN8A (0.45) | SCN8ASCN10ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551836-A1 | AZABICYCLIC AMINE DERIVATIVES AS NK-1 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-07-13 | — | — | EP | disclosed |
| EP-1551846-A1 | AZABICYCLIC SPIROETHER DERIVATIVES AS RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-07-13 | — | — | EP | disclosed |
| EP-0942733-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING COGNITIVE DISORDERS | MERCK SHARP & DOHME (GB) | 2005-04-27 | — | — | EP | disclosed |
| EP-0941093-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS WITH ANXIETY | MERCK SHARP & DOHME (GB) | 2005-02-09 | — | — | EP | disclosed |
| EP-0941092-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS | MERCK SHARP & DOHME (GB) | 2004-12-29 | — | — | EP | disclosed |
| EP-0942732-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MOVEMENT DISORDERS | MERCK SHARP & DOHME (GB) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004031191-A1 | AZABICYCLIC SPIROETHER DERIVATIVES AS RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031190-A1 | AZABICYCLIC AMINE DERIVATIVES AS NK-1 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| US-6613765-B1 | Administering compounds such as 2-(1-(3,5-bis(trifluoromethyl) phenyl)ethoxy)-3-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4 -triazolo)methyl)morpholine; sustained release antidepressants with side effect reduction | MERCK SHARP & DOHME LIMITED | 2003-09-02 | — | — | US | disclosed |
| US-6555552-B2 | Psychological disorders; analgesics; antiinflammatory agents | MERCK SHARP & DOHME LTD. (GB) | 2003-04-29 | — | — | US | disclosed |
| US-5919781-A | Use of NK-1 receptor antogonists for treating substance use disorders | MERCK SHARP & DOHME LTD. (GB) | 1999-07-06 | — | — | US | disclosed |
| WO-1999000368-A1 | SUBSTITUTED 3-(BENZYLAMINO)PIPERIDINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1999-01-07 | — | — | WO | disclosed |
| WO-1998024444-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SUBSTANCE USE DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024443-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING BIPOLAR DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024447-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING COGNITIVE DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024442-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SEXUAL DYSFUNCTION | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024439-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SEVERE ANXIETY DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024440-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING STRESS DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024446-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MOVEMENT DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024438-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |